Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report by Kuang, Hongyu et al.
Clinical Case Report Medicine®
OPENEarly severe coronary heart disease and
ischemic heart failure in homozygous familial
hypercholesterolemia
A case report
Hongyu Kuang, BMa,b, Xue Zhou, BMa,b, Li Li, BMc, Qijian Yi, MDa,b, Weinian Shou, PhDd, Tiewei Lu, MDa,b,
∗
Abstract
Rationale:Familial hypercholesterolemia (FH) is a common inherited cause of coronary heart disease (CHD) and premature death in
an early age. Nevertheless, an ischemic heart failure (IHF) associated with FH seems to be rare, and an early diagnosis and therapy
could inﬂuence the prognosis.
Patient concerns: In this 13-year-old girl, multiple xanthomas began to develop from the ﬁrst day of birth. Until June, 2017, she
was admitted to our center due to edema, oliguria, and dyspnea during exertion, which was attributed to a recent respiratory
infection.
Diagnosis: Homozygous FH (HoFH), CHD, and IHF.
Interventions: The patient has been treated with statin, ezetimibe, aspirin, and traditional heart failure (HF) medications. In
addition, the beta-blocker was simultaneously administered.
Outcomes:Genotypes of this proband indicated homozygous mutations of low-density lipoprotein receptor (LDLR) and some co-
segregatedmutations, such as vonWillebrand factor (VWF) and ﬁbroblast growth factor receptors. At 6-month follow-up, we found a
decreased level of plasma lipid proﬁle, in addition to a signiﬁcant improvement in 6-minute walk distance and functional class.
Echocardiography indicated nonsigniﬁcant improvements in the structure and function of the heart.
Lessons: This case report indicates that HoFH can lead to dramatically progressive endothelial damages and ventricular
remodeling, severe atherosclerosis, even IHF. Genetic outcomes indicate IHF with HoFH could possibly result from LDLR mutations
and some co-segregated mutations inﬂuencing endothelial function and cardiovascular remodeling. In a short-term follow-up, a
combination of statins, ezetimibe, aspirin, and traditional HF agents is safe and effective for IHF with HoFH, and there is a need for
further identiﬁcation of drugs to ameliorate endothelial function and cardiovascular remodeling which may play an important role in
long-term treatment.
Abbreviations: BNP = B-type natriuretic peptide, CHD = coronary heart disease, FC = functional class, FGFR = ﬁbroblast
growth factor receptor, FH = familial hypercholesterolemia, HF = heart failure, HoFH = homozygous FH, IHF = ischemic heart
failure, LDL-C = low-density lipoprotein cholesterol, LDLR = low-density lipoprotein receptor, LVEF= left ventricular ejection fraction,
VWF = von Willebrand factor PSCK-9 = protein convertase subtilisin kexin type 9.
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11. Introduction
Familial hypercholesterolemia (FH) has been identiﬁed as an
autosomal dominant disorder that leads to predisposing
accelerated atherosclerosis and premature coronary heart disease
(CHD). FH may be caused by mutations in the low-density
lipoprotein receptor (LDLR), resulting in an extreme elevation of
low-density lipoprotein cholesterol (LDL-C) levels.[1] Most
people with FH are diagnosed based on high cholesterol levels
because they present no visible symptoms. Additionally,
heterozygous FH is a frequent monogenic hereditary disorder
in the general population with a prevalence of approximately 1/
200 subjects; conversely, homozygous FH (HoFH) is a rare
condition with a prevalence of approximately 1/1,000,000.[2–4]
Symptoms including multiple xanthomas in the tendons, skin,
and eyelids, and rarely the arcus cornea are speciﬁc to FH. The
clinical diagnosis mainly is based on cholesterol levels.
Endothelial dysfunction begins from conception in FH patients,
particularly in HoFH individuals; it progressively causes
Figure 1. Multiple xanthomas in elbows (A) and pateller (B).
Kuang et al. Medicine (2018) 97:42 Medicinepremature aortic valvular stenosis and coronary atherosclerosis,
and even early death. We are highlighting this case because there
were no symptoms of acute myocardial ischemia, but the patient
experienced chronic heart failure (HF). Currently, a 13-year-old
girl with severe CHD and ischemic HF (IHF) was admitted to the
Department of Cardiology, Children’s Hospital of Chongqing
Medical University in June, 2017, for a history of edema,
oliguria, and dyspnea; she had never previously exhibited any
chest pain or discomfort or palpitation. Eventually, the patient
obtained a good prognosis using a combined therapeutic strategy
of high-dose statins, ezetimibe, and drugs for HF. The patient has
provided informed consent for the publication of this report.2. Case report
A 13-year-old girl from a city in western China had a history of
edema, oliguria, and dyspnea during exertion for 9 days, which
was attributed to a recent respiratory infection. Surprisingly, the
child had experienced multiple xanthomas from the ﬁrst day of
birth, with a progressive expansion. The ﬁrst-degree relatives
(parents, the little brother, and the elder sister) were free from
similar nodular xanthomas, and no speciﬁc family history of
CHD was notable.Table 1
Lipid proﬁle of index case compared with the standard of normality
Case Total cholesterol, mmol/L Triglyceride, mmo
Index case 14.73 1.41
Father 9.16 2.79
Mother 6.85 0.81
Sister 6.57 0.51
Brother 5.13 0.59
Normal range 2.7–5.5 0.3–1.8
Pediatric FH
∗
>6.7 —
Plasma lipid was examined by homogeneous enzyme immunoassay with HDL-Cholesterol plus 3rd gen
FH= familial hypercholesterolemia, HDL=high-density lipoprotein, LDL= low-density lipoprotein.
∗
According to Simon Broome familial hypercholesterolemia register diagnostic criteria for familial hyper
2Currently, she is 151cm tall and weighs 41kg (body mass
index 18.0). Her baseline exercise capacity was assessed: she was
classiﬁed as functional class (FC) III, which is associated with a 6-
minute walk distance of 212 to 240m. A physical examination
revealed the following data: T: 36.8°C; P: 122 beats per minute;
R: 29 times per minute; blood pressure: 106/64mm Hg.
There were multiple xanthomas around the tendons of her feet,
hands, elbows, patellar, and buttocks, with a maximum diameter
of 55mm (Fig. 1). On cardiac examination, the apex beat was
detected in the left intercostal space 3mm outside the middle of
the clavicle, with a limited beating range. Mild to moderate
edema was present in the lower limbs.
Examinations revealed high levels of C-reaction protein (59
mg/L) and procalcitonin (1.138ng/mL). Furthermore, a signiﬁ-
cant elevation of her plasma lipid proﬁle was detected and is
shown in Table 1 and Fig. 2. B-type natriuretic peptide (BNP) was
elevated to 558.73pg/mL, which is in accordance with a clinical
diagnosis of HF. Electrocardiograph marked apparent ST
segment changes, and echocardiography indicated a diffuse
ventricular and atrial hypertrophy, which is associated with a
signiﬁcant decrease of left ventricular ejection fraction (LVEF) as
31%. Diffuse atherosclerotic burden and stenosis, and calciﬁed
changes were detected in computed tomography (CT) and CTand FH concentration.
l/L LDL-cholesterol, mmol/L HDL-cholesterol, mmol/L
13.44 0.59
7.64 0.88
5.41 1.24
5.06 1.54
3.76 1.16
0–3.1 0.91–2.27
>4.0 —
eration (HDLC3), triglycerides (TRIGL), LDL-Cholesterol plus second generation (LDL_C).
cholesterolemia (FH).[6]
Figure 2. The chart of the proband and affected kindred based on phenotypes).
Kuang et al. Medicine (2018) 97:42 www.md-journal.comangiography in the ascending aorta, descending aorta, and
coronary arteries, as shown in Fig. 3. A fatal stenosis was present
in 93% of the main trunk in the left coronary artery, 65% in the
left anterior descending (LAD) branch, and 42% in the right
coronary artery (RCA), which was caused by atherosclerosis.Figure 3. Imaging characteristics of the proband, including ECG (A), echocardiog
CT=computed tomography.
3Genomic DNA samples were sheared and then hybridized to
enrich the exonic DNA. Consent was obtained from the patient
and her parents. In addition, an ethics committee (Children’s
Hospital Medical University) approved this study. The DNA
libraries were tested for enrichment using qPCR and for sizeram (B), and CT (C and D) (arrow: the calciﬁcation changes in multiple arteries).
Table 2
Phenotype and genotypes of affected kindred.
Age (y) Mucocutaneous Phenotype
∗
Genotype
Index case 13.7 Xanthomas Ho FH LDLR AA
Father 52 Normal He FH LDLR Aa
Mother 42 Normal He FH LDLR Aa
Brother 11 Normal Basically Normal LDLR Aa
Sister 20 Normal He FH LDLR Aa
FH= familial hypercholesterolemia, HeFH=heterozygous FH, HoFH=homozygous FH, LDLR= low-density lipoprotein receptor.
∗
Based on the clinically diagnostic guideline respectively in adults and children.
Kuang et al. Medicine (2018) 97:42 Medicinedistribution and concentration using an Agilent Bioanalyzer
2100. Then, exon-enriched DNA was sequenced by the Illumina
hiseq2500 platform following the manufacturer’s instructions
(Illumina). Raw image ﬁles were processed using BclToFastq
(Illumina) for base calling and generating the raw data. The low-
quality variations were removed using a quality score ≥20 (Q20).
The sequencing reads were aligned to the NCBI (www.ncbi.nlm.
nih.gov) human reference genome (hg19) using BWA. Sanger
sequencing was used to conﬁrm the mutated genes of the
proband. The genotypes of the proband and affected kindred
are shown in Table 2. The homozygous form (2 mutated
alleles) was indicated in the proband’s genotype, and the
heterozygous form (unilateral mutated allele) was indicated in
the proband’s ﬁrst-grade relatives for the LDLR function chr-19:
11216237–11216242, c.655 (exon4)_c.660 (exon4)delGGC-Figure 4. The mutation site of the FH proband and proband’s ﬁrst-grade relatives (
delGGCCCC; Father/Mother/Sister/Brother: sequence of the heterzygous muta
olemia.
4CCC, p.219Ala_220Prodel; rs879254617 (Fig. 4); these genes
were possibly tightly linked to some co-segregated mutations
inﬂuencing endothelial function and cardiovascular remodeling.
Six genetic mutations displayed this phenotype: ﬁbroblast growth
factor receptor (FGFR)-2 (chr-10:123353406–123353406, c.75
(exon2) C>T, rs41287990), von Willebrand factor (VWF) (chr-
12, 6647238- 6647238, c.6644 (exon17) C>T, rs201703764),
DCHS1 (chr-11, 6103273–6103273, c.6353 (exon37) G>A,
rs375779188), TTN (chr-2, 179640101–179640101, c.6490
(exon28) G>A, rs56285559), VHL (chr-3, 10183649–
10183649, c.118 (exon1) C>G) and DNAJB6 (chr-7,
157178324–157178324, c.710 (exon8) G>A, rs199612810).
The proband patient was administered atorvastatin (20mg/d),
ezetimibe (20mg/d), and traditional HF medications, such as
digoxin, diuretics, and angiotensin-converting enzyme inhibitorProband: sequence of the homozygous mutation (c.655 (exon4)_c.660 (exon4)
tion (c.655 (exon4)_c.660 (exon4)delGGCCCC). FH= familial hypercholester-
Kuang et al. Medicine (2018) 97:42 www.md-journal.com(ACEI). She was simultaneously treated with aspirin. Addition-
ally, beta-blockers were administered to prevent ventricular
remodeling. After 6 months, her total cholesterol levels decreased
by approximately 11.7% (from 14.73 to 13.0mmol/L), her LDL-
C levels decreased by 14.3% (from 13.44 to 11.52mmol/L), and
her high-density lipoprotein cholesterol levels increased from
0.59 to 0.73mmol/L. Clinically, her exercise capacity and FC
signiﬁcantly improved. When assessing cardiac structure,
echocardiography indicated nonsigniﬁcant improvements in
cardiac hypertrophy (left ventricular dilation 64 vs 61mm)
and cardiac function (LVEF 43% vs 31%).3. Discussion
Familial hypercholesterolemia is a disease characterized by
lifelong elevated cholesterol levels; therefore, it is a potential
cause of premature CHD.[5] There are 3 well-known interna-
tional criteria regarding FH diagnosis, and the Simon Broome
standard was applied in the current case, which includes the
family history, clinical signs, the cholesterol concentration levels,
and genotype.[6] Mutations in the LDLR, apolipoprotein B, and
protein convertase subtilisin kexin type 9 genes have been noted
in patients with FH. As mentioned above, a point mutation in the
LDLR gene is commonly identiﬁed, and more than 1600
mutations have been documented worldwide. The LDLR gene
consists of 18 exons, and the encoding key proteins are involved
in the LDLR endocytic and recycling pathways [1,7–9].
A defective LDLR has been noted with elevated cholesterol
concentrations, especially LDL-C, which impairs endothelial
function and leads to premature CHD. Coronary arterial stenosis
and acute myocardial infarction are the most common
complications threatening FH cases; moreover, the genotype
identiﬁed as HoFH in LDLR mutations could lead to progressive
cardiovascular impairments and chronic HF. Clinically, the
patient manifested edema and exercise dyspnea as an inducer of
recent respiratory infection; there was no history of chest pain or
acute ischemic damages. A series of laboratory and imaging
ﬁndings identiﬁed chronic HF with an elevated BNP, enlarged
ventricular and damaged LVEF. Proofs indicated that IHF was
possibly caused by severe CHD at early stages and other potential
factors. The pathological mechanism may be related to the
dysfunctional endothelial cells and cardiomyocytes that lead to
cardiac ischemia and reperfusion, progressive remodeling of
cardiomyocytes, and cardiac dysfunction.[10] Unlike previous
cases of HoFH, the cardiovascular lesions may have resulted
from the cosegregated mutations inﬂuencing endothelial function
and cardiovascular remodeling linked to LDLRmutations. VWF,
which was ﬁrst described in the 1900s, is proposed as a risk factor
of cardiovascular diseases. It is selectively produced in ECs
implicated in the pathogenesis of atherosclerosis, further
promoting localized inﬂammation and inducing plaque forma-
tion. Also, a mutation of VWF could lead to a decrease level of
plasma VWF, which would contribute to a tendency of
bleeding.[11] Moreover, House et al[12] have demonstrated the
essential role of FGFR-2 in endothelial cells for vascular
remodeling after ischemic injury. FGFRs were shown to be an
essential part of vascular calciﬁcation, arteriosclerotic plaque
formation, ischemia-reperfusion, and myocardial energy metab-
olism characterized by the apoptosis of vascular smooth muscle
cells and cardiac cells.
The pharmacological recommendations include an adequate
dose of statins to reduce the LDL-C concentrations to below
approximately half the baseline level for adults with FH, if5tolerated. If not tolerated, additional drugs such as ezetimibe
should be considered. For children, statins and ezetimibe are also
the ﬁrst-line choice for HoFH to regulate LDL-C levels; however,
the average life expectancy of patients with HoFH is less than 18
years. In this case, a combination therapy of statins and ezetimibe
is efﬁcient to decrease the risk of severe cardiovascular events;
however, this therapy cannot reverse the vascular stenosis,
calciﬁed changes, and chronic ischemic lesions. For such
symptoms of HF induced by respiratory infection, which has
been considered the most common factor, early traditional
medications could relieve symptoms and improve cardiovascular
disorders clinically, and an amelioration of exercise tolerance and
FC grade was reported during a short-term follow-up. However,
nonsigniﬁcant improvements in ventricular enlargement and
ejection function were detected, which required a further
treatment and follow-up.
Hence, the current study provides further support that HoFH
can lead to dramatically elevated plasma cholesterol concen-
trations and cardiovascular events, even IHF, at an early age.
However, a good prognosis during a short-term follow-up is
possible with a combination therapy of statins, ezetimibe, aspirin,
and drugs for HF. Furthermore, it is identiﬁed that beta-blockers
can delay the progress of structural and functional cardiovascular
changes. Additionally, the co-segregated mutations in VWF and
FGFR-2 may aggravate the endothelial lesions and cardiovascu-
lar remodeling, causing IHF eventually. Consequently, the drugs
to modulate the VWF levels and ameliorate nutrition for vascular
smooth muscle cells and cardiac cells could be considered for
patients with HoFH and IHF. When necessary, plasma exchange
and a heart-liver transplantation are further options for HoFH
with refractory CHD.Acknowledgments
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